All individual numbers are from the SEC provided Financial Statement and Notes Data Sets. No guarantee is made for their accuracy. This report only shows the values that are common to a significant number of companies.
ACUMEN PHARMACEUTICALS, INC. Last Reported: 1/31/2024 Stock Symbol: ABOS

Business Address

427 PARK ST.

CHARLOTTESVILLE , VA US 22902

Mailing Address

427 PARK ST.

CHARLOTTESVILLE , VA US 22902
Phone Number: 925-368-8508 / State Incorporated: DE / Fiscal Year End 12 /31

Balance Sheet

Date 9/30/2023 6/30/2023 12/31/2022 9/30/2022 6/30/2022 12/31/2021 9/30/2021 6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Cash and Cash Equivalents $94,917,000.00 -- -- $157,540,000.00 $111,067,000.00 $122,162,000.00 $135,802,000.00 $68,812,000.00 -- $43,777,000.00 $1,959,000.00 $3,242,000.00 -- $6,552,000.00
Accounts Receivable Net Current -- -- -- -- -- -- -- -- -- -- -- -- -- --
Inventory -- -- -- -- -- -- -- -- -- -- -- -- -- --
Prepaid Expenses and Other Current Assets $3,164,000.00 $4,657,000.00 $2,724,000.00 $2,366,000.00 $1,142,000.00 $4,424,000.00 $4,840,000.00 $1,651,000.00 -- $543,000.00 -- -- -- --
Total Current Assets $218,598,000.00 $149,538,000.00 $180,329,000.00 $202,560,000.00 $191,053,000.00 $198,661,000.00 $204,913,000.00 $70,572,000.00 -- $44,429,000.00 -- -- -- --
Property Plant and Equipement $123,000.00 $136,000.00 $165,000.00 $142,000.00 $113,000.00 $36,000.00 $13,000.00 $6,000.00 -- -- -- -- -- --
Intangible Assets Net -- -- -- -- -- -- -- -- -- -- -- -- -- --
Goodwill -- -- -- -- -- -- -- -- -- -- -- -- -- --
Other Assets $189,000.00 $208,000.00 $151,000.00 $92,000.00 $106,000.00 $14,000.00 $13,000.00 $13,000.00 -- -- -- -- -- --
Total Assets $286,371,000.00 $177,405,000.00 $196,587,000.00 $203,264,000.00 $211,678,000.00 $230,330,000.00 $234,849,000.00 $72,943,000.00 -- $44,429,000.00 -- -- -- --
Accounts Payable $1,362,000.00 $2,026,000.00 $1,640,000.00 $2,084,000.00 $1,710,000.00 $1,088,000.00 $382,000.00 $2,907,000.00 -- $531,000.00 -- -- -- --
Accrued Liabilities $3,168,000.00 $2,374,000.00 -- -- -- -- -- -- -- -- -- -- -- --
Total Current Liabilities $6,098,000.00 $8,531,000.00 $7,812,000.00 $6,613,000.00 $5,159,000.00 $5,147,000.00 $1,489,000.00 $4,518,000.00 -- $6,367,000.00 -- -- -- --
Long Term Debt -- -- -- -- -- -- -- -- -- -- -- -- -- --
Additional Paid-in Capital -- -- -- -- -- -- -- -- -- -- -- -- -- --
Accumulated Other Comprehensive Loss $-509,000.00 $-646,000.00 -- -- -- -- $-28,000.00 -- -- -- -- -- -- --
Accumulated Deficit $-206,300,000.00 $-193,344,000.00 $-170,400,000.00 $-157,600,000.00 $-146,851,000.00 $-127,571,000.00 $-119,222,000.00 $-115,300,000.00 -- $-27,000,000.00 -- -- -- --
Total Stockholders' Equity $280,273,000.00 $168,874,000.00 $188,775,000.00 $196,651,000.00 $206,519,000.00 $225,183,000.00 $233,360,000.00 $-106,079,000.00 $-45,462,000.00 $-18,591,000.00 $-17,874,000.00 $-15,423,000.00 $-13,426,000.00 $-11,420,000.00
Controlling Interest in Subsidiaries -- -- -- -- -- -- -- -- -- -- -- -- -- --
Total Liabilities and Equity $286,371,000.00 $177,405,000.00 $196,587,000.00 $203,264,000.00 $211,678,000.00 $230,330,000.00 $234,849,000.00 $72,943,000.00 -- $44,429,000.00 -- -- -- --

Statement of Operations

Date 9/30/2023 6/30/2023 12/31/2022 9/30/2022 6/30/2022 12/31/2021 9/30/2021 6/30/2021 3/31/2021 12/31/2020 9/30/2020 6/30/2020 3/31/2020 12/31/2019
Total Revenues -- -- -- -- -- -- -- -- -- -- -- -- -- --
Cost of Revenues -- -- -- -- -- -- -- -- -- -- -- -- -- --
Gross Profit -- -- -- -- -- -- -- -- -- -- -- -- -- --
Research and Development $11,179,000.00 $17,846,000.00 $32,361,000.00 $21,615,000.00 $13,306,000.00 $12,305,000.00 $1,800,000.00 $4,832,000.00 -- -- $6,971,000.00 $1,927,000.00 -- --
Selling, General, and Administrative -- -- -- -- -- -- -- -- -- -- -- -- -- --
Total Operating Expenses $16,039,000.00 $13,478,000.00 $45,237,000.00 $30,989,000.00 $10,411,000.00 $19,584,000.00 $11,169,000.00 $7,234,000.00 -- -- $3,220,000.00 $2,186,000.00 -- --
Loss from Operations $-42,652,000.00 $-13,478,000.00 $-45,237,000.00 $-30,989,000.00 $-10,411,000.00 $-19,584,000.00 $-3,935,000.00 $-7,234,000.00 -- -- $-2,490,000.00 $-4,081,000.00 -- --
Loss Before Income Taxes -- -- -- -- -- -- -- -- -- -- -- -- -- --
Earnings Per Share Basic $-0.79 $-0.28 $-1.06 $-0.74 $-0.25 -- -- -- -- -- -- -- -- --
Weighted Average Shares Basic 54,229,630 41,025,062 40,601,936 40,491,181 40,485,244 -- -- -- -- -- -- -- -- --
Earnings Per Share Diluted $-0.79 $-0.28 $-1.06 $-0.74 $-0.25 -- -- -- -- -- -- -- -- --
Weighted Average Shares Diluted 45,474,953 41,025,062 40,601,936 40,502,860 40,497,087 -- -- -- -- -- -- -- -- --
Common Stock Shares Authorized 300,000,000 300,000,000 300,000,000 300,000,000 300,000,000 300,000,000 300,000,000 50,500,000 -- 50,500,000 -- -- -- --
Common Stock Shares Outstanding 57,910,461 41,025,062 41,025,062 40,503,124 40,501,258 40,473,270 40,470,323 556,570 -- 419,124 -- -- -- --
Common Stock Value $6,000.00 $4,000.00 $4,000.00 $4,000.00 $4,000.00 $4,000.00 $4,000.00 -- -- -- -- -- -- --
Common Stock Par Or Stated Value Per Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 -- $0.00 -- -- -- --
Payments Of Dividends Common Stock -- -- -- -- -- -- -- -- -- -- -- -- -- --
Preferred Stock Shares Authorized 10,000,000 10,000,000 10,000,000 10,000,000 10,000,000 10,000,000 10,000,000 -- -- -- -- -- -- --
Preferred Stock Shares Outstanding -- -- -- -- -- -- -- -- -- -- -- -- -- --
Preferred Stock Value -- -- -- -- -- -- -- -- -- -- -- -- -- --
Preferred Stock Par Or Stated Value Per Share $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 -- -- -- -- -- -- --
Share Price -- -- -- -- -- -- -- -- -- -- -- -- -- --
Copyright 2024 PursePoor.com